Translational Session
New Therapies for the Treatment of Type 1 Diabetes and CKD
October 23, 2026 | 04:30 PM - 06:00 PM
Location: Four Seasons Ballroom 1, Convention Center
Session Description
Although new therapies for CKD associated with type 2 diabetes have emerged, many cannot be used by patients with type 1 diabetes. However, new clinical trials are assessing the efficacy and safety of novel interventions for CKD in patients with type 1 diabetes. This session reviews pathophysiological differences and similarities of CKD in type 1 and type 2 diabetes and summarizes potential new kidney- and cardiovascular-protective interventions for patients with type 1 diabetes and CKD.
Learning Objective(s)
- Compare the pathophysiological differences and similarities of CKD in type 1 and type 2 diabetes
- Analyze clinical trials in type 1 diabetes and CKD that target aldosterone with aldosterone synthase inhibitors and mineralocorticoid receptor antagonists (RAs)
- Summarize the role of the incretin system and GIP/GLP-1 RAs for the treatment of type 1 diabetes and CKD
Learning Pathway(s)
- Cardiovascular-Kidney-Metabolic (CKM) Health
- Pharmacology
Moderators
Presentations
- Similarities and Differences in the Pathophysiology of CKD in Type 1 vs. Type 2 Diabetes
04:30 PM - 04:50 PM
- How to Develop New Therapies for Type 1 Diabetes: Challenges and Opportunities
04:50 PM - 05:10 PM
- Update on Nonsteroidal Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibition for the Treatment of Type 1 Diabetes and CKD
05:10 PM - 05:30 PM
- Progress and Opportunities with Novel Incretins in Type 1 Diabetes and CKD
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM